Nia Warfield, Luke Kawa

4/28/25

US stocks shake off early tech slump to finish flat

Monday was shaping up to be a reversal of last week’s price action, with markets trending deeply negative amid a retreat in the megacap tech names that had powered gains the prior week. But from 1:30 p.m. ET onward, a switch flipped and stocks ground higher, with the S&P 500 and Nasdaq 100 finishing virtually flat. The Russell 2000 outperformed with a 0.4% gain.

Consumer staples and tech were the lone S&P 500 sector ETFs to finish in the red; energy, real estate, and utilities were the top performers.

Pharma heavyweights AbbVie, Centene, and Gilead were among the S&P 500’s top movers, helping anchor the broader market. Nvidia shares, meanwhile, fell as much 4% after reports surfaced that Huawei is preparing an AI chip to challenge the tech giant’s blockbuster H100 GPU, but cut those losses in half by the close. Tesla did one better, fully erasing its losses of 4% to end positive.

Beaten-down hydrogen fuel cell company Plug Power spiked as much as 40% in Monday trading as investors cheered preliminary Q1 earnings results.

Domino’s shares slid in early trading after the pizza giant topped Q1 earnings but missed sales estimates — though the stock clawed back those losses by the close.

On Holding jumped higher after Citi said the trendy Swiss sneaker brand’s strong pricing power and loyal consumer base should help it outrun the threat of tariffs.

Bank of America slashed its price target on trucking firm Saia by nearly 50% after the company suffered its biggest stock drop on record on Friday, falling another 2% on Monday.

Elsewhere, Palantir has once again topped the S&P 500 leaderboard, with a nearly 30% surge this month pushing the defense and AI software giant back into contention for the index’s crown.

More Markets

See all Markets

markets

14h

Robinhood, AppLovin, and Emcor pop on announcement of addition to S&P 500

Shares of Robinhood Markets, AppLovin, and Emcor are all rallying in post-market trading on Friday upon news that they’re being added to the S&P 500.

Shares of the brokerage popped 7.2%, the adtech company rose 7.8%, and the construction company was up a more modest 2.7% in the minutes following the announcement.

(Robinhood Markets, Inc. is the parent company of Sherwood Media, an independently operated media company subject to certain legal and regulatory restrictions.)

Strategy, another stock rumored to be in the running for inclusion in the benchmark US stock index that has been passed over, sank 2.5% in postmarket trading.

Nia Warfield, Luke Kawa

S&P 500 falls as rate-cut optimism fizzles

The S&P 500 gave up early gains to close down 0.3%, while the Nasdaq 100 eked out a 0.1% advance and the Russell 2000 outperformed, rising 0.5%.

Brown bear on a rock

markets

16h

Kenvue plunges after reports suggest RFK Jr. may try to link prenatal Tylenol use to autism

Kenvue sank 15% Friday after a WSJ report said Health and Human Services Secretary Robert F. Kennedy Jr. may attempt to link prenatal Tylenol use to autism in an upcoming government report.

Kenvue, the maker of Tylenol and formerly a division of Johnson & Johnson prior to a 2023 spin-out, pushed back, saying the science shows “no causal link” between acetaminophen use during pregnancy and autism, and pointed to FDA and medical groups that agree on the drug’s safety.

The FDA itself has found no “clear evidence” of harm but advises pregnant women to consult providers before taking OTC meds.

The report is also expected to float a folate-derived therapy as a potential treatment.

Tylenol is just the latest well-established medication to face scrutiny under Kennedy, who has already stirred controversy by reshaping vaccine policy and amplifying doubts about mRNA shots.

Kenvue shares are now down over 18% year-to-date.

RFK Jr., HHS to Link Autism to Tylenol Use in Pregnancy and Folate Deficiencies

RFK Jr.

The FDA itself has found no “clear evidence” of harm but advises pregnant women to consult providers before taking OTC meds.

The report is also expected to float a folate-derived therapy as a potential treatment.

Tylenol is just the latest well-established medication to face scrutiny under Kennedy, who has already stirred controversy by reshaping vaccine policy and amplifying doubts about mRNA shots.

Kenvue shares are now down over 18% year-to-date.

markets

17h

Lucid surges following 6 days of losses after headlines misidentify Cantor Fitzgerald’s lower split-adjusted price target as a good thing

It’s been a shortened week, but still a rough one for Lucid. Investor blowback to the luxury EV maker’s 1-for-10 reverse stock split has sent shares to all time lows this week.

After six straight days of closing lower, Wall Street appears to have decided enough is enough and is loading up on Lucid shares on Friday, sending them up 13% in recent trading. As of 2:10pm eastern, Lucid trading volumes were at more than 240% of their 30 day average.

Some of the move could be attributed to traders reading headlines that don’t take into consideration Lucid’s reverse split. Cantor Fitzgerald on Friday slapped a new price target on Lucid of $20, compared to its previous target of $3. Some news outlets (not us!) presented that as an increase. The problem: With the 1-for-10 reverse split in effect, a comparable price target would have been $30. The new $20 target is actually... a cut.

Palantir slips under 50-day moving average, amid momo reversal

What goes up, doesn’t always keep going up.

Palantir CEO Alex Karp PLTR insane valuation

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.

©2025 Sherwood Media, LLC